CELLIBRIUM BIOSCIENCES

What this means for you

This application is over — abandoned 28 Jul 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number

90795404

Mark type

Stylized text

Filed

25 Jun 2021

Published for opposition

26 Apr 2022

Abandoned

28 Jul 2025

Attorney of record

Jessica L. Rothstein

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neurological diseases and neurodegenerative diseases; pharmaceutical preparations, namely, preparations for use in the treatment of Amyotrophic Lateral Sclerosis (ALS); pharmaceutical preparations, namely, B cell therapies for the treatment of neuroinflammation and immune dysregulation; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for the treatment of autoimmune diseases and traumatic brain injuries
• Class 042 — Scientific and technological services: Pharmaceutical research and development; Research and development services in the field of cell therapy

Owner

• Cellibrium Biosciences, Inc., East Walpole, MA, US
• Cellibrium Biosciences, Inc., Dedham, MA, US

Prosecution history

• 28 Jul 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
• 28 Jul 2025 — ABANDONMENT - NO USE STATEMENT FILED
• 04 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 03 Mar 2025 — SOU EXTENSION 5 GRANTED
• 20 Nov 2024 — SOU EXTENSION 5 FILED
• 03 Mar 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
• 20 Nov 2024 — SOU TEAS EXTENSION RECEIVED
• 01 May 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 30 Apr 2024 — SOU EXTENSION 4 GRANTED
• 30 Apr 2024 — SOU EXTENSION 4 FILED
• 30 Apr 2024 — SOU TEAS EXTENSION RECEIVED
• 28 Nov 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 26 Nov 2023 — SOU EXTENSION 3 GRANTED
• 26 Nov 2023 — SOU EXTENSION 3 FILED
• 26 Nov 2023 — SOU TEAS EXTENSION RECEIVED